Further, analysis from two lung cancer cohorts (“Ruppin 2021” for LUAD and GSE126044 for NSCLC) revealed that low ACAP1 expression was significantly associated with decreased response rate and worse OS/PFS in patients treated with anti-PD-1 antibodies (Figure 9F,G). Here, ACAP1 is linked to lung cancer.